Search Result

Results for "

ankylosing

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Btk (1) Carbonic Anhydrase (1) Caspase (1) COX (7) Epigenetic Reader Domain (1) Histone Acetyltransferase (1) Interleukin Related (8) Isotope-Labeled Compounds (2) Phosphatase (1) Prostaglandin Receptor (1)
By Research Areas:	Cancer (4) Infection (2) Inflammation/Immunology (20)

Inhibitors & Agonists

Inhibitory Antibodies

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-B0634

Aceclofenac	COX	Inflammation/Immunology
Aceclofenac is an orally active nonsteroidal anti-inflammatory agent (NSAID), with analgesic and anti-inflammatory properties. Aceclofenac is used for the research of osteoarthritis, ankylosing spondylitis, rheumatoid arthritis .

HY-141535A

IL-17 modulator 1 disodium	Interleukin Related	Infection Inflammation/Immunology
IL-17 modulator 1 (disodium) is an orally active, highly efficacious IL-17 modulator extracted from patent WO 2020127685. IL-17 modulator 1 (disodium) can be used for the research of diseases including psoriasis, ankylosing spondylitis and psoriatic arthritis .

HY-109143B

(R)-Elsubrutinib (R)-ABBV-105	Btk	Inflammation/Immunology Cancer
(R)-Elsubrutinib ((R)-ABBV-105) is a Btk inhibitor. (R)-Elsubrutinib can be used in studies of immune diseases (such as rheumatoid arthritis, psoriasis, ankylosing spondylitis, asthma, systemic lupus erythematosus) and cancer .

HY-127150

Clofezone Perclusone	Others	Inflammation/Immunology
Clofezone (Perclusone) is a antirheumatic agent. Clofezone can be used in the study of various rheumatic diseases, especially arthritis (RA) and ankylosing spondylitis (AS) .

HY-P99754

Netakimab	Interleukin Related	Inflammation/Immunology
Netakimab is an anti-IL-17 monoclonal antibody. Nerelimomab can be used for research of ankylosing spondylitis, psoriatic arthritis, moderate-to-severe plaque psoriasis .

HY-141535

IL-17 modulator 1	Interleukin Related	Infection Inflammation/Immunology
IL-17 modulator 1 is an orally active, highly efficacious small molecule IL-17 modulators extracted from patent WO 2020127685. IL-17 modulator 1 can be used for the research of preventing, researching or ameliorating a variety of diseases including psoriasis, ankylosing spondylitis and psoriatic arthritis .

HY-B0230

Phenylbutazone	COX	Inflammation/Immunology
Phenylbutazone is an efficient reducing cofactor for the peroxidase activity of prostaglandin H synthase (PHS). Phenylbutazone, a hepatotoxin, is a nonsteroidal anti-inflammatory agent (NSAID). Phenylbutazone induces muscle blind-like protein 1 (MBNL1) expression and has the potential for ankylosing spondylitis research .

HY-158159

IL17A-IN-1	Interleukin Related	Inflammation/Immunology Cancer
IL17A-IN-1 (compound 72) is an orally active Interleukin 17A inhibitor. IL17A-IN-1 can be used in the study of inflammatory and autoimmune diseases (plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis, etc.), as well as cancer .

HY-W009706

Alclofenac Allopydin; W-7320	Prostaglandin Receptor	Inflammation/Immunology
Alclofenac (Allopydin) is a non-steroidal anti-inflammatory agent (NSAID). Alclofenac is a prostaglandin H2 synthase inhibitor. Alclofenac can be used for rheumatoid arthritis, degenerative joint disease and ankylosing spondylitis research .

HY-B0634S

Aceclofenac-d4	Isotope-Labeled Compounds COX	Inflammation/Immunology
Aceclofenac-d₄ is the deuterium labeled Aceclofenac. Aceclofenac is an orally active nonsteroidal anti-inflammatory agent (NSAID), with analgesic and anti-inflammatory properties. Aceclofenac is used for the research of osteoarthritis, ankylosing spondylitis, rheumatoid arthritis[1][2].

HY-P99652

Gumokimab AK 111	Interleukin Related	Inflammation/Immunology
Gumokimab (AK 111) is a monoclonal antibody targeting IL-17A, which can be used in the study of psoriasis, ankylosing spondylitis. Gumokimab competitively blocks the binding of human IL-17A to IL-17R.

HY-P9927

Secukinumab AIN457	Interleukin Related	Inflammation/Immunology Cancer
Secukinumab (AIN457) is a high affinity, human monoclonal antibody targeted against interleukin (IL)-17A. Secukinumab is the first-in-class anti-IL-17 agent used for the research of plaque psoriasis, ankylosing spondylitis and psoriatic arthritis .

HY-B0230S2

Phenylbutazone-13C12	COX	Inflammation/Immunology
Phenylbutazone- ¹³C₁₂ is the ¹³C₁₂ labeled Phenylbutazone. Phenylbutazone is an efficient reducing cofactor for the peroxidase activity of prostaglandin H synthase (PHS). Phenylbutazone, a hepatotoxin, is a nonsteroidal anti-inflammatory agent (NSAID). Phenylbutazone induces muscle blind-like protein 1 (MBNL1) expression and has the potential for ankylosing spondylitis research.

HY-P99335

Vunakizumab Anti-Human IL17A Recombinant Antibody	Interleukin Related	Inflammation/Immunology
Vunakizumab (Anti-Human IL17A Recombinant Antibody) is a recombinant human IgGκ monoclonal antibody that targets IL-17A and inhibits its interaction with the IL-17 receptor. Vunakizumab can be used to study autoimmune diseases such as psoriatic arthritis, ankylosing spondylitis, multiple sclerosis and inflammatory arthritis .

HY-B0230S

Phenylbutazone(diphenyl-d10)	COX	Inflammation/Immunology
Phenylbutazone(diphenyl-d₁₀) is the deuterium labeled Phenylbutazone. Phenylbutazone is an efficient reducing cofactor for the peroxidase activity of prostaglandin H synthase (PHS). Phenylbutazone, a hepatotoxin, is a nonsteroidal anti-inflammatory agent (NSAID). Phenylbutazone induces muscle blind-like protein 1 (MBNL1) expression and has the potential for ankylosing spondylitis research[1][2].

HY-B0230S1

Phenylbutazone-d9	Isotope-Labeled Compounds COX	Inflammation/Immunology
Phenylbutazone-d₉ is the deuterium labeled Phenylbutazone. Phenylbutazone is an efficient reducing cofactor for the peroxidase activity of prostaglandin H synthase (PHS). Phenylbutazone, a hepatotoxin, is a nonsteroidal anti-inflammatory agent (NSAID). Phenylbutazone induces muscle blind-like protein 1 (MBNL1) expression and has the potential for ankylosing spondylitis research[1][2].

HY-P99280

Bimekizumab Anti-Human IL17A/IL-17F Recombinant Antibody	Interleukin Related	Inflammation/Immunology
Bimekizumab (Anti-Human IL17A/IL-17F Recombinant Antibody) is a humanised monoclonal antibody, can selectively neutralises IL-17A and IL-17F. Both of them are pro-osteogenic with respect to human periosteum-derived cell (hPDC) differentiation. Thus Bimekizumab blocks the inflammation-driven osteogenic differentiation .

HY-B1138

Fenbufen CL-82204	COX Caspase	Inflammation/Immunology
Fenbufen (CL-82204) is an orally active non-steroidal anti-inflammatory drug (NSAID), with analgetic and antipyretic effects. Fenbufen has potent activity in a variety of animal model, including carageenin edema, UV erythema and adjuvant arthritis. Fenbufen has inhibitory activities against COX-1 and COX-2 with IC₅₀s of 3.9 μM and 8.1 μM, respectively. Fenbufen is a caspases (caspase-1, 3, 4, 5, 9) inhibitor .

HY-157139

ALP/Carbonic anhydrase-IN-1	Carbonic Anhydrase Phosphatase	Inflammation/Immunology
ALP/Carbonic anhydrase-IN-1 (Compound 1e) is a dual carbonic anhydrase (CA) and alkaline phosphatase (ALP) inhibitor. ALP/Carbonic anhydrase-IN-1 shows IC₅₀ values of 0.44 µM, 1.61 µM, 0.51 µM, and 0.107 µM for CA-II, CA-IX, CA-XII, and ALP, respectively .

HY-15826

SGC-CBP30 10+ Cited Publications	Epigenetic Reader Domain Histone Acetyltransferase	Inflammation/Immunology Cancer
SGC-CBP30 is a potent and highly selective CBP/p300 bromodomain (K_ds of 21 nM and 32 nM for CBP and p300, respectively) inhibitor, displaying 40-fold selectivity over the first bromodomain of BRD4 [BRD4(1)] bound. SGC-CBP30 strongly reduces secretion of IL-17A in Th17 cells and has anti-inflammatory effects .

Secukinumab AIN457	Interleukin Related	Inflammation/Immunology Cancer
Secukinumab (AIN457) is a high affinity, human monoclonal antibody targeted against interleukin (IL)-17A. Secukinumab is the first-in-class anti-IL-17 agent used for the research of plaque psoriasis, ankylosing spondylitis and psoriatic arthritis .

Vunakizumab Anti-Human IL17A Recombinant Antibody	Interleukin Related	Inflammation/Immunology
Vunakizumab (Anti-Human IL17A Recombinant Antibody) is a recombinant human IgGκ monoclonal antibody that targets IL-17A and inhibits its interaction with the IL-17 receptor. Vunakizumab can be used to study autoimmune diseases such as psoriatic arthritis, ankylosing spondylitis, multiple sclerosis and inflammatory arthritis .

Bimekizumab Anti-Human IL17A/IL-17F Recombinant Antibody	Interleukin Related	Inflammation/Immunology
Bimekizumab (Anti-Human IL17A/IL-17F Recombinant Antibody) is a humanised monoclonal antibody, can selectively neutralises IL-17A and IL-17F. Both of them are pro-osteogenic with respect to human periosteum-derived cell (hPDC) differentiation. Thus Bimekizumab blocks the inflammation-driven osteogenic differentiation .

Netakimab	Interleukin Related	Inflammation/Immunology
Netakimab is an anti-IL-17 monoclonal antibody. Nerelimomab can be used for research of ankylosing spondylitis, psoriatic arthritis, moderate-to-severe plaque psoriasis .

Gumokimab AK 111	Interleukin Related	Inflammation/Immunology
Gumokimab (AK 111) is a monoclonal antibody targeting IL-17A, which can be used in the study of psoriasis, ankylosing spondylitis. Gumokimab competitively blocks the binding of human IL-17A to IL-17R.

Phenylbutazone-13C12
Phenylbutazone- ¹³C₁₂ is the ¹³C₁₂ labeled Phenylbutazone. Phenylbutazone is an efficient reducing cofactor for the peroxidase activity of prostaglandin H synthase (PHS). Phenylbutazone, a hepatotoxin, is a nonsteroidal anti-inflammatory agent (NSAID). Phenylbutazone induces muscle blind-like protein 1 (MBNL1) expression and has the potential for ankylosing spondylitis research.

Phenylbutazone(diphenyl-d10)
Phenylbutazone(diphenyl-d₁₀) is the deuterium labeled Phenylbutazone. Phenylbutazone is an efficient reducing cofactor for the peroxidase activity of prostaglandin H synthase (PHS). Phenylbutazone, a hepatotoxin, is a nonsteroidal anti-inflammatory agent (NSAID). Phenylbutazone induces muscle blind-like protein 1 (MBNL1) expression and has the potential for ankylosing spondylitis research[1][2].

Aceclofenac-d4
Aceclofenac-d₄ is the deuterium labeled Aceclofenac. Aceclofenac is an orally active nonsteroidal anti-inflammatory agent (NSAID), with analgesic and anti-inflammatory properties. Aceclofenac is used for the research of osteoarthritis, ankylosing spondylitis, rheumatoid arthritis[1][2].

Phenylbutazone-d9
Phenylbutazone-d₉ is the deuterium labeled Phenylbutazone. Phenylbutazone is an efficient reducing cofactor for the peroxidase activity of prostaglandin H synthase (PHS). Phenylbutazone, a hepatotoxin, is a nonsteroidal anti-inflammatory agent (NSAID). Phenylbutazone induces muscle blind-like protein 1 (MBNL1) expression and has the potential for ankylosing spondylitis research[1][2].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.